Dynamic Technology Lab Private Ltd lessened its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 59.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,630 shares of the company's stock after selling 26,264 shares during the period. Dynamic Technology Lab Private Ltd owned approximately 0.06% of Castle Biosciences worth $470,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Castle Biosciences by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock worth $48,837,000 after buying an additional 83,783 shares during the period. Principal Financial Group Inc. raised its position in shares of Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock worth $43,879,000 after acquiring an additional 40,377 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Castle Biosciences in the 4th quarter valued at about $19,244,000. State Street Corp boosted its position in shares of Castle Biosciences by 9.8% in the 3rd quarter. State Street Corp now owns 680,001 shares of the company's stock worth $19,394,000 after purchasing an additional 60,924 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Castle Biosciences by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 628,196 shares of the company's stock valued at $16,746,000 after buying an additional 3,513 shares during the last quarter. Institutional investors own 92.60% of the company's stock.
Castle Biosciences Stock Performance
Shares of CSTL stock traded up $0.27 during trading hours on Monday, reaching $19.97. 19,013 shares of the company's stock were exchanged, compared to its average volume of 376,291. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The company has a market cap of $575.91 million, a P/E ratio of 99.85 and a beta of 1.11. The company's 50 day moving average is $22.34 and its two-hundred day moving average is $27.09.
Wall Street Analyst Weigh In
Several analysts have commented on the stock. Stephens restated an "overweight" rating and set a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Guggenheim set a $30.00 price objective on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Finally, Robert W. Baird upped their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences currently has a consensus rating of "Buy" and a consensus price target of $38.75.
Check Out Our Latest Analysis on CSTL
Insider Transactions at Castle Biosciences
In other Castle Biosciences news, insider Derek J. Maetzold sold 22,639 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the completion of the transaction, the insider now directly owns 80,465 shares in the company, valued at approximately $1,618,955.80. The trade was a 21.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Insiders have sold 34,085 shares of company stock valued at $748,045 in the last quarter. 7.20% of the stock is currently owned by corporate insiders.
Castle Biosciences Company Profile
(
Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
